# Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure

> **NCT02775539** · PHASE2 · UNKNOWN · sponsor: **Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III** · enrollment: 80 (estimated)

## Conditions studied

- Pulmonary Hypertension
- Mirabegron
- Heart Failure
- Pulmonary Vascular Resistance Abnormality

## Interventions

- **DRUG:** Mirabegron
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02775539
- **Lead sponsor:** Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2017-01
- **Final completion:** 2019-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2016-05-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02775539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02775539, "Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT02775539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*